Jiangsu Recbio Technology Co – based in the Taizhou Medical High-tech Zone, in Taizhou city, in East China's Jiangsu province – will join forces with Shanghai Rongsheng Biotech Co Ltd in Shanghai.
Together they'll develop new adjuvant vaccines, according to a statement released at the agreement signing ceremony on March 25.
New adjuvants are widely seen as being key to the successful development of innovative vaccines.
Under the agreement, the two will jointly develop new adjuvant vaccines. For its part, Recbio Technology will provide independently developed new adjuvants based on a new adjuvant technology platform and Rongsheng will supply its independently designed virus antigens.
The project was expected to boost existing vaccines under development by Rongsheng with new adjuvants – to improve immunogenicity and achieve the goal of optimizing immunization procedures.
Founded in 1988, Rongsheng is a national high-tech enterprise engaged in the research and development, production and sales of vaccines and in vitro diagnostic reagents.
Recbio is an innovative vaccine company driven by independent R&D technology as its core driving force. It's one of the few international companies with the ability to develop and produce a full range of new adjuvants.
At present, it has established three innovative platforms – for new adjuvants, protein engineering as well as immune evaluations.
Jiangsu Recbio Technology Co joins hands with Shanghai Rongsheng Biotech Co Ltd to develop new adjuvant vaccines. [Photo/Taizhou Medical High-tech Zone via WeChat weigg6666]